Two oral trofosfamide schedules in elderly patients with refractory non- Hodgkin's lymphoma

Onkologie

Volumn 22, Issue 2, 1999, Pages 134-138

  Wiedemann, G J ^d   Zschaber, R ^d   Hegewisch Becker, S ^d   Reichardt, P ^d   Weber, K ^d   Uthgenannt, D ^d   Lowenstrom O ^a   Jager E ^b   Freund, M ^d   Seeger, R ^a   Feller, A C ^d   Merz, H ^d   Hartlapp, J H ^d   Wagner, T ^d   Illiger, H J ^c  

^a ASTA MEDICA AG   (Germany)

^b KRANKENHAUS NORDWEST   (Germany)

^c KLINIKUM OLDENBURG   (Germany)

^d NONE

Author keywords

Elderly patients; Non Hodgkin's lymphoma; Trofosfamide

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; PREDNISOLONE; TROFOSFAMIDE;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RECURRENCE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOPENIA; MALE; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; THROMBOCYTOPENIA; TREATMENT PLANNING;

EID: 0032951563     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000026942     Document Type: Article

References (18)

1. Pines A, Ben-Bassat I, Modan M, Blumstein T, Ramot B: Survival and prognostic factors in chronic lymphocytic leukemia. Eur J Haematol 1987;38: 123-130.
2. Molica S, Barngiatelli M; Callea V: Comparison of younger versus older B-cell chronic lymphocytic leukemia patients for clinical presentation and prognosis. A restrospective study of 53 cases. Eur J Haematol 1994;52:216-221.
3. Catovsky D, Fooks J, Richards R: Prognostic factors in chronic lymphocytic leukemia: The importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. Br J Haematol 1989;72:141-149.
4. Salminen E: The outcome of treatment of >70 years old non-Hodgkin's lymphoma patients. Int J Radiat Oncol Biol Phys 1995;32:349-353.
5. Hiddemann W: Non-Hodgkin's lymphomas - current status of therapy and future perspectives. Eur J Cancer 1995;31A:2141-2145.
6. Dixon DO, Neilan B, Jones SE: Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: The Southwest Oncology Group experience. J Clin Oncol 1986;4:295-305.
7. Solal-Celigny F, Chastang C, Herrera A: Age as the main prognostic factor in adult aggressive non-Hodgkin's lymphoma. Am J Med 1987;83: 1075-1079.
8. Wist E, Risberg T: Trofosfamide in non-Hodgkin's lymphoma. Acta Oncol 1991;7:819-821.
9. Salminen E, Nikkanen V, Lindholm L: Trofosfamide is effective in refractory non-Hodgkin's lymphoma. Eur J Cancer 1995;31A:2419-2420.
10. Salminen E, Nikkanen V, Lindholm L: Palliative chemotherapy in non-Hodgkin's lymphoma. Oncology 1997;54:108-111.
11. Norum J: Complete remission after repeated trofosfamide treatment in relapsing high-grade malignant non-Hodgkin's lymphoma - a case report. Acta Oncol 1994;33:831.
12. Helsing MD: Trofosfamide as a salvage treatment with low toxicity in malignant lymphoma. A phase II study. Eur J Cancer 1997;33:500-502.
13. Brock N: Oxazaphosphorine cytostatics: Past -present - future. Cancer Res 1989;49:1-7.
14. Boos J, Kupker F, Blaschke G, Jrgens H: Trofosfamide metabolism in different species - ifosfamide is the predominant metabolite. Cancer Chemother Pharmacol 1993;33:71-76.
15. Wiedemann GJ, Zschaber R, Hegewisch-Becker S, Löwenstrom O, Wagner T: Efficacy and safety of two oral trofosfamide schedules in elderly patients (>65 years) with refractory non-Hodgkin's lymphoma. Proc ASCO 1998;17:13A(abstract no. 49).
16. Lennert K, Feller AC: Histopathology of non-Hodgkin's lymphomas. Berlin, Springer, 1992.
17. World Health Organization (WHO) Handbook for Reporting Results of Cancer Treatment. Geneva, WHO, 1979.
18. Tirelli U, Errante D, Van Glabbeke M; Teodorovic I, Kluin-Nelemans JC, Thomas J, Bron D, Rosti G, Somers R, Zagonel V, Noordijk EM: CHOP is the standard regimen in patients ≥70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: Results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol 1998;16:27-34.